Web Results

GenSpera Announces Name Change to Inspyr Therapeutics

www.inspyrtx.com/news/press-releases/detail/620/genspera-announces-name-change-to-inspyr-therapeutics

Aug 1, 2016 ... GenSpera Announces Name Change to Inspyr Therapeutics ... on building shareholder value,” said Peter E. Grebow, Ph.D., Interim Chairman. ... Inspyr Therapeutics, Inc. (formerly known as GenSpera, Inc.) is developing a ...

GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin

www.inspyrtx.com/news/press-releases/detail/598/genspera-expands-phase-ii-glioblastoma-trial-of-mipsagargin

May 13, 2015 ... SAN ANTONIO, May 13, 2015 /PRNewswire/ -- GenSpera, Inc. (OTCQB: ... Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores ...

Zacks Small Cap Research - NSPX: GenSpera Changes Name to ...

scr.zacks.com/News/Press-Releases/Press-Release-Details/2016/NSPX-GenSpera-Changes-Name-to-Inspyr-Therapeutics-Focused-on-Development-of-Mipsagargin-for-Multiple-Cancer-Indications-article/default.aspx

Aug 19, 2016 ... V - 6. Nuvo Research, Inc. - NRI.TO – 1. Theralase Technology - TLT. ... NSPX: GenSpera Changes Name to Inspyr Therapeutics; Focused ... By David Bautz, PhD ... and coupled to a protease-specific peptide carrier (Denmeade et al., 1998 ). .... On August 1, 2016, GenSpera, Inc. announced it is changing it ...

Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4984914/

Apr 26, 2016 ... ... (ECs) of a variety of solid tumours types (Liu et al, 1997; Chang et al, 1999a, ..... GenSpera, Inc. provided assistance with preparation of this manuscript. ... [ PubMed]; Deniaud A, Sharaf el dein O, Malillier E, Poncet D, Kroemer ... Gill DL, Isaacs JT (1994) The role of calcium, pH, and cell proliferation in the ...

GenSpera changes its name to Inspyr Therapeutics - San Antonio ...

www.mysanantonio.com/business/health-care/article/GenSpera-changes-its-name-to-Inspyr-Therapeutics-9010203.php

Aug 1, 2016 ... San Antonio biotech company GenSpera Inc., which has been working to develop target-specific cancer drugs, revealed today that it will ...

Engineering a Prostate-Specific Membrane Antigen ... - NCBI

www.ncbi.nlm.nih.gov/pmc/articles/PMC3715055/

Purified G202 for animal studies was provided by GenSpera Inc. PSMA fusion ... Inc. Arrays were stained for PSMA according to the method of Milowsky et al. with a .... The role of calcium, pH, and cell proliferation in the programmed (apoptotic) ... Deniaud A, Sharaf el dein O, Malillier E, Poncet D, Kroemer G, Lemaire C, ...

GenSpera, Inc. - The Chairman's Blog

www.thechairmansblog.com/genspera/

GenSpera unlocks conventional thinking to conceive, design, and develop curative cancer therapies that are core ... By Craig A. Dionne, Ph.D. | GenSpera, Inc.

Thapsigargin—From Thapsia L. to Mipsagargin (PDF Download ...

www.researchgate.net/publication/275240902_Thapsigargin-From_Thapsia_L_to_Mipsagargin

thapsigargin extracted from T. garganica has been thoroughly investigated. In 1978, for instance, it was ... from Drew et al. [14] The top sketch illustrates the core ...

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling ...

cancerres.aacrjournals.org/content/73/4/1386

Feb 15, 2013 ... B, comparison of anticancer efficacy of TasQ (10 mg/kg/d via drinking water) ... Reagents: G202 (GenSpera); Tasquinimod (Active Biotech ..... CO2 and decreasing pH, 60% knockdown of HDAC4 decreases survival of ..... Denmeade SR,; Mhaka AM,; Rosen DM,; Brennen WN,; Dalrymple S,; Dach I,; et al.

Engineering a Prostate-Specific Membrane Antigen–Activated ...

stm.sciencemag.org/content/4/140/140ra86

Jun 27, 2012 ... Samuel R. Denmeade,*,; Annastasiah M. Mhaka,; D. Marc Rosen, ... George Wilding,; Michael A. Carducci,; Craig A. Dionne,; Jesper V. Møller,, ...